1. Robert McKinnon Califf was born on 1951 and is an American cardiologist who served as the 25th commissioner of food and drugs from 2016 to 2017 and again from 2022 to 2025.
16 Facts About Robert Califf
1. 2.
Robert Califf was first nominated to be commissioner in September 2015 by President Barack Obama and he was confirmed by the US Senate in February 2016, serving until January 20,2017.
3.
Robert Califf was confirmed by the Senate on February 15,2022.
4.
Robert Califf left North Carolina for an internal medicine residency at the University of California, San Francisco and returned in 1980 to Duke to complete a fellowship in cardiology.
5.
Robert Califf is board-certified in internal medicine and cardiology, and a Master of the American College of Cardiology.
6.
Robert Califf was granted tenure as professor of cardiology at Duke University School of Medicine.
7.
Robert Califf was the full-time head of strategy and policy for its Verily Life Sciences and Google Health divisions.
8.
Robert Califf has led many clinical cardiology research studies, health outcomes research, health care quality, and translational research, which seeks to ensure that advances in science translate into medical care.
9.
Robert Califf is recognized by the Institute for Scientific Information as one of the top 10 most cited medical authors, with more than 1,200 peer-reviewed publications.
10.
Robert Califf was a director of Portola Pharmaceuticals, Inc from July 2012 to January 26,2015, an advisor for Proventys, Inc.
11.
In January 2015, Robert Califf was appointed Deputy Commissioner of the United States Food and Drug Administration's Office of Medical Products and Tobacco, "second in scope only to being commissioner".
12.
In February 2015, Robert Califf was cited as a possible successor to Margaret Hamburg, the outgoing commissioner of food and drugs.
13.
Robert Califf stepped down from the post of FDA commissioner on January 20,2017.
14.
Robert Califf is a member of the Institute of Medicine.
15.
Robert Califf was on the committees that recommended, for example, Medicare coverage of clinical trials and to remove ephedra from the market, and the committee on identifying and preventing medication errors.
16.
Robert Califf served on the FDA Cardiorenal Advisory Panel and FDA Science Board's Subcommittee on Science and Technology.